Search the Newsreel

ConocoPhillips Picks Its Next CEO With Big Projects Looming

ConocoPhillips has appointed CFO Andy O’Brien as its new CEO, effective September 1, a transition occurring as the company manages significant projects. A key focus for O'Brien will be the $9 billion Willow project in Alaska, which is central to ConocoPhillips' goal of generating …

EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal

Aspire Biopharma Holdings (NASDAQ: ASBP) has completed its $30 million acquisition of Dura Driver Control Systems (DCS), marking its entry into the automotive and mobility-control market. The deal makes DCS a wholly-owned subsidiary, expected to add significant revenue, earnings, and cash flow to Aspire's …

Sei Investments Co. Buys Shares of 357,888 SOPHiA GENETICS SA $SOPH

Sei Investments Co. has acquired 357,888 shares of SOPHiA GENETICS SA (NASDAQ:SOPH) for approximately $1.77 million, giving it a 0.52% stake in the company. Despite this institutional investment, SOPHiA GENETICS remains unprofitable, reporting a quarterly loss of $0.26 per share, worse than estimates, although …

Theravance Biopharma (TBPH) Earnings Date and Reports 2026

New ConocoPhillips CEO inherits US$7 billion cash flow pledge riding on Alaska oil project

Andy O’Brien is set to become ConocoPhillips' new CEO next month, succeeding Ryan Lance. O'Brien faces the critical task of completing the costly Willow oil project in Alaska, which is essential for the company to achieve its US$7 billion free cash flow target by …

ConocoPhillips’s Q2 Earnings Doubled the Buyback to $2 Billion.

ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ABVC Biopharma Inc (ABVC), focusing on future EPS and revenue growth estimates. It includes current stock information, market capitalization, and a peer comparison from the biotechnology and medical research sector. The forecast sections cover expected EPS, revenue, …

ConocoPhillips acaba de superar las previsiones de beneficio por acción en un 6,1 %: esto es lo que los analistas creen que sucederá a continuación

ConocoPhillips Just Beat EPS By 6.1%: Here's What Analysts Think Will Happen Next

ConocoPhillips (NYSE:COP) recently reported its quarterly results, with revenues meeting analyst predictions and statutory profit exceeding expectations at US$3.23 per share. Analysts have subsequently become more bullish, increasing their 2026 EPS forecast by 34% to US$10.30, though the consensus price target remains unchanged at …

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Aspire Biopharma Holdings, Inc. announced the launch of its BUZZ BOMB(TM) Convenience Store Pack, expanding its retail presence in the energy category. BUZZ BOMB(TM) is a dry powder caffeine product delivered in single-serving stick packs designed for sublingual use, offering a rapid caffeine boost …

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts

Eleven analysts have given Vor Biopharma Inc. (NASDAQ:VOR) a consensus rating of "Moderate Buy," with an average 12-month price target of $42.25. The stock opened at $23.67, with recent analyst actions including Jefferies upgrading it to "strong buy" and Wedbush raising its target price …

Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates

Lyell Immunopharma (NASDAQ: LYEL) reported second-quarter earnings per share of $-1.920, exceeding analyst estimates by $0.22. However, the company's revenue of $4K fell short of the consensus estimate of $5.5K. Despite a 23.580% drop in its stock price over the last three months, Lyell …

XTLB Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a financial overview of X T L Biopharmaceuticals Ltd (XTLB), detailing its revenue breakdown, profitability margins, and a comparison with competitors. XTLB generates most of its revenue from Operating Segment / Medical Devices, with a negative contribution of -$589.00K. The company's …

Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS

Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock

Estrella Immunopharma Inc (ESLA) Stock News Today

This article provides current stock information for Estrella Immunopharma Inc (ESLA), noting its recent price of $0.723 USD, a drop of 4.01%. It mentions that news and analysis, financials, stock score, technical forecast, ownership, dividends, and profile information are available, with more news expected …

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts

Connect Biopharma Holdings Limited (NASDAQ:CNTB) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $7.29, significantly higher than its current price of $2.20. Director James Huang recently purchased 150,000 shares, boosting insider ownership to 22.60%. Despite missing …

Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP

Dawson Geophysical (NASDAQ:DWSN) Stock Passes Above 200 Day Moving Average - Here's Why

Dawson Geophysical (NASDAQ:DWSN) shares have risen above their 200-day moving average, reaching $4.85 and closing at $4.35, significantly higher than the $3.74 average. The company recently surpassed earnings expectations with an EPS of $0.25 against a projected $0.29 loss and revenues of $36.7 million …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7% - Here's What Happened

Immix Biopharma (NASDAQ: IMMX) saw its stock price drop by 6.7% to $9.39 during midday trading on Friday, with trading volume significantly lower than average. Despite this decline, analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of …

Cue Biopharma Inc (CUE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cue Biopharma Inc (CUE), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights an expected revenue of $3.00M for the next quarter, an average price target of $5.00, and a "Buy" trend …

Lepu Biopharma Schedules Board Meeting to Review 2026 Interim Results and Potential Dividend

Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings, reporting an EPS of ($0.18), which slightly missed the consensus estimate of ($0.17). Following the news, shares dropped 3.4% to $9.72, significantly below the average analyst target price of $20.71. Despite the earnings miss, the company holds …

Connect Biopharma Holdings Ltd (CNTB) Stock News Today

This article provides current stock information for Connect Biopharma Holdings Ltd (CNTB), including its stock price, market cap, and links to financial data, analyst ratings, and news. It indicates that more news will be available soon for the company.

Dawson Geophysical Co (DWSN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Dawson Geophysical Co (DWSN), focusing on future EPS and revenue growth estimates. It includes current stock data, market capitalization, P/E ratio, and a comparison with peer companies in the Oil & Gas Related Equipment and Services sector. …

Cue Biopharma Inc (CUE) Stock News Today

This article provides current stock news for Cue Biopharma Inc (CUE), including its stock price, market cap, and recent performance. It also lists "Amgen Inc Stock (AMGN) Opened Down by 4.69% on May 1: A Full Analysis" as a relevant news item. The piece …

Dawson Geophysical Co (DWSN) Stock News Today

Benitec Biopharma Inc (BNTC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Benitec Biopharma Inc (BNTC), highlighting its current earnings forecast score of 8.86 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $27.00 for BNTC, with a majority recommending a "Buy" trend. …

ConocoPhillips (COP) Stock Price Meets Cash Flow Ambition And Project Risk

FMR LLC discloses 12% VOR Biopharma (VOR) stake for Abigail P. Johnson

FMR LLC and Abigail P. Johnson have each reported beneficial ownership of 12.0% of VOR Biopharma Inc.'s common stock, totaling 6,509,996 shares, according to a Schedule 13G/A filing. FMR LLC exercises sole voting power over most of these shares and sole dispositive power over …

SUTRO BIOPHARMA INC : STIFEL INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $48

Stifel has initiated coverage on Sutro Biopharma Inc. (STRO.O) with a Buy rating. The investment firm has set a price target of $48 for the biopharmaceutical company's stock. This indicates a positive outlook from Stifel regarding Sutro Biopharma's future performance.

Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash

SOPHiA GENETICS (SOPH) insider plans Rule 144 sale after 10b5-1 trades

SOPHiA GENETICS (SOPH) has filed a Form 144 indicating a proposed sale of 20,000 common shares with an aggregate market value of $133,800.00, anticipated on August 7, 2026. This filing also details previous Rule 10b5-1 plan sales by Jurgi Camblong, including significant transactions on …

Immix Biopharma Q2 FY26 net loss widens to USD 11.56 million; G&A expense more than doubled to USD 7.12 million

Immix Biopharma reported a widened net loss of USD 11.56 million for Q2 FY26, compared to USD 6.62 million in the previous year. This increase was primarily driven by general and administrative expenses more than doubling to USD 7.12 million due to higher compensation …

RedHill Biopharma (RDHL) investors back all AGM resolutions in 2026

RedHill Biopharma Ltd. announced that all resolutions proposed at its adjourned Annual General Meeting of Shareholders on August 7, 2026, were duly approved. This includes the re-appointment of auditors, re-election of board members, approval of Dror Ben-Asher as Chairman and CEO, and an amendment …

Mereo BioPharma Group PLC (MREO) Stock News Today

This article provides current stock information for Mereo BioPharma Group PLC (MREO), including its stock price, market cap, and a note that more news is coming soon. The page serves as a hub for news, analysis, financials, and other investment-related data for the company.